Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032-Reference-Cited by-同舟云学术

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032

Published:2011-05 Issue:5 Volume:77 Page:1172-1176
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Smith David C.,Tangen Cathy M.,Van Veldhuizen Peter J.,Harrer Grant W.,Golshayan Ali,Mills Glenn M.,Vogelzang Nicholas J.,Thompson Ian M.,Hussain Maha H.A.

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162);Hussain;J Clin Oncol,2006

2. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer;Millikan;J Clin Oncol,2008

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance;International Journal of Molecular Sciences;2020-11-16

2. Etoposide Loaded SPION‐PNIPAM Nanoparticles Improve the in vitro Therapeutic Outcome on Metastatic Prostate Cancer Cells via Enhanced Apoptosis;Chemistry & Biodiversity;2020-10-15

3. Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer;Therapeutic Advances in Medical Oncology;2019-01

4. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2018-12

5. A Case of Ischemic Heart Disease in Hormone Treatment with Castration Resistant Prostate Cancer;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2015